Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10480MR)

This product GTTS-WQ10480MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10480MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8772MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ11377MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ2176MR IVTScrip™ mRNA-Anti-IL15RA, ALT-803(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ALT-803
GTTS-WQ453MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 3G3
GTTS-WQ12469MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA NN-8226
GTTS-WQ12039MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ15891MR IVTScrip™ mRNA-Anti-SLC34A2, XMT-1536(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA XMT-1536
GTTS-WQ613MR IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 7F3com-2H2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW